Evidence map›Paper›PMID 33258581›Full record

ArticleACS infectious diseases2020

Structural Optimization of 2,3-Dihydro-1H-cyclopenta[

Xionghao Lin, Ayyiliath M Sajith, Songping Wang, Namita Kumari, Meng S Choy, Asrar Ahmad, Dana R Cadet, Xinbin Gu, Andrey I Ivanov, Wolfgang Peti and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Xionghao LinCenter for Sickle Cell Disease, College of Medicine, Howard University, Washington, DC 20059, United States.
Ayyiliath M SajithDepartment of Pharmaceutical Sciences, College of Pharmacy, Howard University, Washington, DC 20059, United States.
Songping WangCenter for Sickle Cell Disease, College of Medicine, Howard University, Washington, DC 20059, United States.
Namita KumariCenter for Sickle Cell Disease, College of Medicine, Howard University, Washington, DC 20059, United States.
Meng S ChoyDepartment of Chemistry and Biochemistry, University of Arizona, Tucson, Arizona 85721 United States.
Asrar AhmadCenter for Sickle Cell Disease, College of Medicine, Howard University, Washington, DC 20059, United States.
Dana R CadetDepartment of Natural Science, Bowie State University, Bowie, Maryland 20715, United States.
Xinbin GuDepartment of Oral Pathology, College of Dentistry, Howard University, Washington, DC 20059, United States.
Andrey I IvanovCenter for Sickle Cell Disease, College of Medicine, Howard University, Washington, DC 20059, United States.
Wolfgang PetiDepartment of Chemistry and Biochemistry, University of Arizona, Tucson, Arizona 85721 United States.ORCID 0000-0002-8830-6594
Amol KulkarniDepartment of Pharmaceutical Sciences, College of Pharmacy, Howard University, Washington, DC 20059, United States.
Sergei NekhaiCenter for Sickle Cell Disease, College of Medicine, Howard University, Washington, DC 20059, United States.ORCID 0000-0003-0744-7887
Howard University · USUniversity of Arizona · USBowie State University · US

Funding

Treatment of HIV- and HIV+ Patients with HPV16+ CIN2/3 Using pNGLV4a-hCRTE6E7L2 DNA vaccine administered intramuscularly via electroporationP50CA098252 · NCI · JOHNS HOPKINS UNIVERSITY · PI TZYY-CHOOU WU · 2003 to 2026
$53.5M
Sleep Disorders in Adults with Sickle Cell Disease: Frequency, Associations with Cardiovascular and Pain Indicators, and Responses to TreatmentU54MD007597 · NIMHD · HOWARD UNIVERSITY · PI Tatiana V.D. Sanses · 2019 to 2026
$37.7M
SWG 2: Cure Research Scientific Working GroupP30AI117970 · NIAID · GEORGE WASHINGTON UNIVERSITY · PI Italo Mocchetti · 2015 to 2026
$29.6M
Therapeutics Targeting Filoviral interferon-antagonist and replication functionsU19AI109664 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BASLER, CHRISTOPHER F · 2014 to 2018
$15.8M
Center for Hemoglobin Research in Minorities (CHaRM)P50HL118006 · NHLBI · HOWARD UNIVERSITY · PI NEKHAI, SERGEI · 2013 to 2017
$7.0M
Sickle Cell Disease and Sickle Cell Trait Protection Against HIV-1-infection in Africans and African AmericansR01HL125005 · NHLBI · HOWARD UNIVERSITY · PI MARINA A JEREBTSOVA, SERGEI NEKHAI · 2014 to 2026
$6.7M
Protein Phosphatase 1 Holoenzyme Formation and Subunit ExchangeR01GM134683 · NIGMS · UNIVERSITY OF ARIZONA · PI PETI, WOLFGANG · 2019 to 2020
$564k
Howard University Summer Research Experience Program in Oral Health Disparity for Underrepresented Racial and Ethnic StudentsR25DE025778 · NIDCR · HOWARD UNIVERSITY · PI GU, XINBIN, WU, TZYY-CHOOU · 2016 to 2020
$264k
NCI NIH HHS P50 CA098252NHLBI NIH HHS P50 HL118006NHLBI NIH HHS R01 HL125005NIAID NIH HHS P30 AI117970NIAID NIH HHS U19 AI109664NIDCR NIH HHS R25 DE025778NIGMS NIH HHS R01 GM134683NIMHD NIH HHS U54 MD007597
6 · The paper itself

Abstract

Combination antiretroviral therapy (cART) suppresses human immunodeficiency virus-1 (HIV-1) replication but is unable to permanently eradicate HIV-1. Importantly, cART does not target HIV-1 transcription, which is reactivated in latently infected reservoirs, leading to HIV-1 pathogenesis including non-infectious lung, cardiovascular, kidney, and neurodegenerative diseases. To address the limitations of cART and to prevent HIV-1-related pathogenesis, we developed small molecules to target the noncatalytic RVxF-accommodating site of protein phosphatase-1 (PP1) to prevent HIV-1 transcription activation. The PP1 RVxF-accommodating site is critical for the recruitment of regulatory and substrate proteins to PP1. Here, we confirm that our previously developed

Indexed as

HIV-1QuinolinesHumansProtein Phosphatase 1ProteinsProtein Phosphatase 1ProteinsQuinolinesHIV-1 transcriptionprotein phosphatase-1RVxF-accommodating sitestructural optimization

Identifiers

PMID33258581
PMCPMC7769123
OpenAlexW3107792875

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.